drugset / Trial / NCT00073944
BCX-1777 in Treating Patients With Refractory Cancer
Open-labelTreatment
Summary
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
Timeline
- Start
- 2003-04
- Primary completion
- 2005-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | forodesine | Small molecule | — | Oral |